INTRODUCTION
Indications have arisen from in vitro studies that prostaglandin El (PGE,)1 blunts the ability of vasopressin to increase water permeability of the distal nephron (1, 2) . Experiments in our laboratory have recently shown that drugs that inhibit prostaglandin synthesis potentiate the in vivo hydro-osmotic action of vasopressin in the anesthetized dog (3) . This finding supports the concept that renal prostaglandins modulate tubular responsiveness to vasopressin. One of the mechanisms by which they might do so is suggested by the experiments of Beck et al. with rat medullary tissue slices (2) . This in vitro study showed that PGE1 impaired the ability of vasopressin to stimulate production of its intracellular mediator, 3',5'-cyclic AMP (cyclic AMP). If ). The vasopressin used throughout the study was obtained from a single batch. 7-10 min after the vasopressin injection, at a time when the antidituresis was approachinlg its peak, the kidneys were removed and the meduillas were analyzed for cyclic AMP content as previously described.
Indornethacini plus uasopressin group. The animals in this grouip were given a constant inftusion of 0.45% saline throuighouit the stuidy as described for the previouis three groups. After 30 min of stable water diuresis, 2.0 mg/kg of indomethacin was given intravenously as in the Indomethacin group. After an additional 30 min of recorded, stable water diuresis, the animals were given 200 uU of vasopressin intravenously. 10 min after the vasopressin injection the kidneys were removed and the medullas analyzed for cyclic AMP as described previously. In six additional animals treated in this manner, clearance measurements of inulin and para-aminohippurate (PAH) were carried out for the purpose of estimating glomerular filtration rate and effective renal plasma flow, respectively. The protocols for the above four groups are summarized in Fig. 1 .
Finally, renal medullary tissues from six rats in the Control group, the Indomethacin group, the Vasopressin group, and the Indomethacin plus vasopressin group were assayed for phosphodiesterase (PDE) activity according to the method of Thompson Fig. 4 . This demonstrates the potentiating effect of indomethacin on the hydro-osmotic and medullary cyclic AMP responses to vasopressin. Fig. 5 summarizes the glomerular filtration rate, PAH clearance, and arterial blood pressure data. Indomethacin, alone, had no demonstrable effect on any of these parameters. Vasopressin, when given together with indomethacin, caused a significant rise in arterial pressure, but did not affect glomerular filtration rate or PAH clearance. Table I compares the medullary PDE activity of control rats with that of rats in the Indomethacin group, the Vasopressin group, and the Vasopressin plus indomethacin group as well as the group treated with aminophylline. Neither indomethacin nor vasopressin nor indomethacin plus vasopressin had any demonstrable effect on PDE activity, while aminophylline suppressed it to about one-third of the control value.
DISCUSSION
A great deal of evidence indicates that cyclic AMP mediates the action of antidiuretic hormone on renal tubules and other epithelial membranes (10) (11) (12) (13) . In vitro studies have shown that PGE, impairs the ability of vasopressin to stimulate cyclic AMP production (2) . Because of this latter phenomenon, studies have been undertaken in our laboratory to determine the physiological significance of the interaction between vasopressin and endogenous renal prostaglandins. That such an interaction may be important is suggested not only by the findings of in vitro experiments, but by the fact that the renal medulla and papilla, the primary sites of action of vasopressin, are also sites of abundant prostaglandin synthesis (14) .
In an initial series of experiments performed on anesthetized dogs, we demonstrated that inhibitors of prostaglandin synthesis, namely indomethacin and sodium meclofenamate, greatly potentiate the in vivo hydroosmotic action of vasopressin (3). The present study was undertaken to investigate further the mechanism involved in this effect. One possible mechanism is that inhibition of prostaglandin synthesis causes a decrease in medullary blood flow (15, 16) which then enhances the hypertonicity of the medullary interstitium. This increased osmotic gradient would facilitate the osmotic movement of water across the collecting ducts into the interstitium and thereby enhance the ability of vasopressin to promote urine concentration. If such a purely hemodynamic mechanism accounted for the potentiation of vasopressin activity in vivo by prostaglandin inhibition, the cellular interactions of prostaglandins with vasopressin which have been demonstrated in vitro (2, 15, 17) would be of doubtful in vivo physiological significance. Against this hemodynamic mechanism, however, is the recent finding that indomethacin enhances the in vivo action of vasopressin in the conscious rat, a setting in which the drug has not been found to alter renal hemodynamics (18) .
The present study was undertaken in the rat to examine whether inhibition of prostaglandin synthesis with indomethacin (19, 20) enhances the in vivo effect of vasopressin to increase simultaneously Uosm and medullary concentration of cyclic AMP. Such an in vivo finding would provide strong evidence that prostaglandin inhibition acts by enhancing the cellular effect of vasopressin.
The present results did demonstrate that pretreatment of water diuresing rats with indomethacin resulted in both a significantly greater rise in Uosm and medullary cyclic AMP concentration. As expected from previous studies (19, 20) , these effects of indomethacin were associated with a profound fall in the medullary concentration of prostaglandins. This effect of indomethacin to suppress medullary prostaglandin, as vasopressin-induced increases in Uosm and cyclic AMP were enhanced, is compatible with the hypothesis of Grantham and Orloff (1) that endogenous prostaglandins impair the cellular action of vasopressin to stimulate cyclic AMP production. An alternative explanation, however, was also examined in the present study. The enhanced cyclic AMP response to vasopressin after indomethacin treatment may have been due to an effect of the drug to inhibit the degradation of cyclic AMP, rather than to enhance its production. This possibility was tenable since large doses of indomethacin administered in vitro have been found to inhibit PDE, the degradative enzyme of cyclic AMP (21, 22) . Against this interpretation, however, was the observation in the present study that the administration of indomethacin alone did not increase the medullary concentration of cyclic AMP. This finding could be interpreted to exclude an effect of indomethacin to decrease medullary PDE activity, since, if this were the case, indomethacin alone might have been expected to increase medullary cyclic AMP concentrations. Such an interpretation is, however, not totally justifiable since other inhibitors of cyclic AMP PDE, such as aminophylline, may increase cyclic AMP only in the vasopressin-stimulated state. Thus, it was necessary to determine directly the effect of indomethacin on medullary tissue PDE activity. With the dose of indomethacin which enhanced the hydro-osmotic and cyclic AMP generating effects of vasopressin, the medullary tissue PDE levels were found not to be different in the nontreated control and indomethacin-treated groups of rats. This was true whether the indomethacin was given during a water diuresis, when medullary cyclic AMP was suppressed, or during administration of vasopressin when cyclic AMP production was stimulated. The possibility remains, and cannot be refuted conclusively by our experiments, that the results of our PDE assays do not reflect the activity of the enzyme in vivo. In preparation for the assay, the tissue extracts were diluted by a factor of 1:40. This dilution would be expected to alter the enzyme activity quantitatively. However, it is important to note that the dilution affected all constituents of the tissue equally. Thus, the enzyme, its endogenous substrate (cyclic AMP) and the indomethacin in the tissue extract were all diluted by a factor of 1:40 so that their relative concentrations in the assay system would be comparable to those existing in vivo. Moreover, the same dilution of the tissue extract was used in all groups of animals studied. Therefore, it seems unlikely that the assay procedure would have introduced a systematic change in the enzyme kinetics which would have obscured an inhibitory effect of indomethacin on PDE. This argument is supported by the fact that aminophylline, when given in vivo, was shown by means of the same assay to cause a marked suppression of PDE activity. While this latter observation is not proof that indomethacin had no inhibitory effect on PDE in our experiments, it does show that the assay is capable of detecting enzyme inhibition after a PDE inhibiting drug is administered in vivo.
On the basis of the present study, therefore, the conclusion seems justifiable that indomethacin potentiates the in vivo hydro-osmotic effects of vasopressin by potentiating the ability of the hormone to stimulate cyclic AMP production. This action of indomethacin was associated with a suppression ofmedullary PGE content, but with no demonstrable suppression of cyclic AMP PDE activity. Thus, suppression of endogenous medullary PGE seems to constitute a pathway whereby indomethacin potentiates the in vivo action of vasopressin. A possible extension of this conclusion is that endogenous renomedullary prostaglandins may be physiological and pathophysiological modulators of the hydroosmotic action of vasopressin.
